Recent reports also showed that Velcade (bortezomib), a drug approved by the Food and Drug Administration for the treatment of multiple myeloma, induces NF-κB, instead of inhibiting as was thought by inducing caspase-dependent mechanisms [38]. This evidence concerns the gene NFKB1 and plasma cell myeloma.